An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the Bioequivalence of AMG 785 Following Subcutaneous Administration of 120 mg/mL Concentration Versus 70 mg/mL Concentration

Sponsor ID

20101180

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 1

Product

romosozumab

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

Location

Status

Location

Research Site

Springfield, MO, United States, 65802

Status

Recruiting